Kinhong

Kinhong Biopharma is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for cancer and immunological disorders. The company utilizes a proprietary structure-based drug design platform to develop highly selective inhibitors for challenging targets, particularly within the RAS/MAPK signaling pathway. Its lead clinical program, KH-617, is a potent SHP2 inhibitor currently being evaluated in Phase 1 trials for the treatment of advanced solid tumors. Kinhong is backed by leading life science investors, including Qiming Venture Partners and Decheng Capital, and aims to provide precision medicine solutions to patients worldwide. The company's research focus extends to other key nodes in oncogenic signaling, such as SOS1 and KRAS.